What's in Mostafa Bahaa's pipeline?

Mostafa Bahaa has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Mostafa Bahaa's portfolio?

Top competitors by shared drug class: Casper Pharma Llc, Takeda.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/mostafa-bahaa.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-13 · How we verify

Mostafa Bahaa — Portfolio Competitive Intelligence Brief

Mostafa Bahaa pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Valsartan 80 mg	Valsartan 80 mg	marketed
Febuxostat Tablets	Febuxostat Tablets	marketed	Xanthine Oxidase Inhibitor [EPC]

Therapeutic area mix

No therapeutic area data.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Casper Pharma Llc · 1 shared drug class
Takeda · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Mostafa Bahaa:

Cite this brief

Drug Landscape (2026). Mostafa Bahaa — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/mostafa-bahaa. Accessed 2026-05-13.